Is ASH's EPS showing a recovery trend for 2025?

**Ashland's EPS is not currently forming a recovery trend for 2025**. The available data and analysis suggest the following points:

1. **Recent Performance**: Ashland's adjusted EPS for the first quarter of fiscal year 2025 was $0.28, which surpassed the forecast of $0.24. However, this was a decrease from the prior-year quarter's adjusted EPS of $0.45.
2. **Challenges and Optimizations**: The company has been implementing portfolio optimization actions, including the review of strategic alternatives for the Avoca business line and the divestiture of its nutraceuticals business. These actions have reduced sales by approximately $24 million but have contributed to a more focused and profitable product lineup.
3. **Market Conditions**: Ashland has faced challenges such as lower pricing and softer demand, particularly in Europe and China. The company's sales in the life sciences segment fell by 33% from the prior year to $134 million, primarily due to portfolio optimization and lower pharmaceutical sales volumes.
4. **Strategic Initiatives**: Despite the challenges, Ashland is focusing on strengthening its global presence, especially in life sciences and emerging markets. The company is also investing in product innovation, with plans to introduce 7 new products in 2025.

In conclusion, while Ashland's EPS has shown a positive surprise in the recent quarter, the overall trend of EPS is decreasing, and the company is facing significant challenges that suggest a recovery trend is not currently forming for 2025. The company's strategic initiatives and optimizations may lead to a recovery in the future, but this is not yet reflected in the EPS data.